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Introduction
The accurate detection of lymph node metastases is
one of the most important challenges in cancer imaging
today, for the presence of nodal disease is a powerful
adverse prognostic indicator. Pre-treatment detection
of malignant nodes determines patient management,
frequently distinguishing surgical candidates from those
best suited to non-surgical therapy. However, the results
of CT and MR imaging have been disappointing with
poor sensitivities and specificities, low sensitivities being
due to the inability to identify metastases in normal-sized
nodes or those that are only minimally enlarged, and
poor specificities resulting from nodal enlargement due
to benign pathology. MR lymphography can demonstrate
small nodal deposits, but the technique remains in the
research arena, requires high-resolution thin sections
to produce good image quality and is expensive. It is
therefore likely to be used, at least for the foreseeable
future, in highly selected patient groups. In order to give
appropriate consideration to the likelihood of a prominent
or enlarged lymph node harbouring a metastasis, it is
incumbent on the radiologist to use all the relevant
information available. This frequently requires discussion
with clinicians or review of the patient’s case notes.
In order to provide the best possible assessment of
nodal status with CT and MR, the radiologist requires
detailed knowledge of: (1) the primary tumour in
terms of the patterns of spread and the incidence of
nodal metastases at different stages of disease; (2) the
characteristic CT/MR features of nodal involvement;
(3) the pitfalls in diagnosis of nodal disease; (4) the
accuracy of imaging and the impact of positive and
negative results on patient management.
The radiologist also needs information on the patient’s
current therapy and previous treatment, as such knowl-
edge may influence interpretation. For example, a patient
who has previously been treated with pelvic radiotherapy
is more likely to relapse in nodes outside the radiotherapy
field, thus the development of nodal enlargement in
the pelvis should be interpreted with caution. It is
also important to know whether the patient has any
coincidental disease that could be a cause of nodal
enlargement.
The primary tumour: patterns of
lymphatic spread and incidence of
nodal involvement
In most pelvic cancers the incidence of nodal involvement
increases with primary tumour stage and is also related
to histological tumour grade and tumour bulk. The
recurrence rate and overall survival are directly related
to nodal spread.
Prostate cancer
Prostate cancer spreads via lymphatics in the neurovas-
cular bundles to the obturator, presacral, hypogastric and
external iliac nodes (Fig. 1). Further spread is to the
common iliac and paraaortic nodes [1].
External iliac nodes are involved in 60% and obturator
nodes in over 50% of node positive cases (Fig. 2) [1].
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Figure 1 Prostate cancer. CT scan showing (a) left obturator nodal involvement and (b) left obturator and
hypogastric nodal spread.
Figure 2 Prostate cancer. T2-weighted MR image
showing a minimally enlarged lymph node in the right
obturator group.
In 10–30% the lateral sacral/presacral nodes are the
only sites of nodal disease; these nodes are not sampled
at pelvic lymph node dissection (PLND) (Fig. 3).
Paraaortic nodes are involved late. They are often the
only sites of nodal involvement at relapse following
pelvic radiotherapy (Table 1) [2].
Table 1 [3,4]
T stage Incidence of nodal metastases (%)
Organ confined disease (T1/T2) <5
Focal capsular penetration 15
(Early T3)
Extracapsular spread (T3) 30
Advanced local disease (T4) >40
e.g. seminal vesicle invasion
At radical prostatectomy, 5–10% of cases have
involved nodes [5,6].
Survival depends on the number of positive nodes: 5-
year disease-free survival-solitary nodal involvement 75–
80%; multiple nodes 20–30%.
High-risk patients have a 50% chance of nodal
involvement. There is also an increased risk in clinical
stage T3 disease.
High and low-risk groups may be used to select patients
for lymphadenectomy and for imaging.
High-risk PSA≥ 20 ng ml−1, Gleason score≥ 7; Low-
risk PSA < 20 ng ml−1, Gleason score <7.
Bladder cancer
Bladder cancer spreads to the paravesical, lateral sacral
and presacral nodes, then to the obturator, hypogastric,
external iliac and common iliac nodes.
Obturator nodes are involved in 75% of those with
nodal disease (Table 2) [1].
Table 2 [7,8]
T stage Incidence of nodal metastases (%)
Superficial tumours (T1) <5
Superficial tumours (T2a) 10–15
Muscle invasion (T2b) 15–20
Extravesical spread (≥T3a/b) 30–50
Adjacent organ invasion (T4) 40–45
Three-year survival with a solitary positive node is
approximately 50%. Survival is reduced to approximately
25% if multiple nodes are involved. Node-negative
patients have survival of approximately 70% [9].
PLND is only beneficial in selected patients with
metastases confined to one or few nodes, as most patients
with nodal metastases already have systemic spread.
Colorectal cancer
A network of lymphatic vessels converge to form
three major channels: (1) lymphatics draining the upper
rectum above the peritoneal reflection drain into the
inferior mesenteric nodes and then to the paraaortic
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Figure 3 Prostate cancer. (a) & (b) T1 and T2-weighted images prior to radiotherapy showing a 1 cm
presacral lymph node. (c) & (d) The same patient post-treatment. The lymph node has regressed considerably
during treatment demonstrating response to radiotherapy.
nodes; (2) middle rectal lymphatics below the peritoneal
reflection drain into the obturator and hypogastric nodes;
(3) lower lymphatic vessels drain the lower rectum and
spread is mainly to the inguinal nodes (Fig. 4) (Table 3).
Table 3 [10]
Tumour stage Incidence of nodal metastases (%)
T1 (superficial into submucosa) 3–10
T2 (muscularis propria) 10–30
T3 (serosal invasion or >50
invasion of perirectal fat)
For lymph node-negative patients with T3 tumours,
survival is approximately 70% compared with 35% if
nodes are positive [11,12].
Survival is significantly better for node-positive
patients with 1–3 nodes involved compared with more
than 3 nodes [12].
Total mesorectal excision is increasingly practised for
rectal cancer with significant reduction in mortality and
recurrence rates [13].
CT/MR findings of nodal involvement
Metastases from pelvic cancers frequently produce little,
if any, nodal enlargement. Enlarged lymph nodes in
the pelvis may be benign, due to reactive hyperplasia
or inflammation. The criteria for assessment of nodal
involvement include: (1) site; (2) size; (3) shape;
(4) number of nodes; (5) nodal characteristics.
Site
The anatomical position of nodes in relation to the pattern
of spread of the primary tumour is important (vide supra).
Size
Pelvic nodes greater than 8 mm in maximum short axis
diameter (MSAD) should be regarded as enlarged on CT
and MR [14]. In two recent studies we have measured
the normal MSAD of nodes in the pelvis on CT and
MR (Table 4) [15,16]. On MR a greater number of smaller
nodes are identified.




Figure 4 (a) Diagram demonstrating pathways of lymphatic spread in rectal cancer. (b) CT scan showing a
T3 rectal cancer. Two pararectal lymph nodes (6 mm in diameter) are shown. (c) T2-weighted MR image also
showing a T3 primary rectal cancer. Note: 6 mm pararectal lymph node on the right. (d) Coronal image in the
same patient showing an 8 mm lymph node in the presacral space (arrow). (e) Sagittal MR image in the same
patient showing the same presacral node (arrow) and another enlarged node inferior to this.
Table 4 [15,16] Normal lymph node size—MRI/CT
95th percentile value—5% FP rate
MRI (mm) CT (mm)
Common iliac 4 6.5
External iliac 5 6.0
Obturator 4 5.1
Internal iliac 5 4.0
Hypogastric 6 —
Shape
Round (spherical) nodes are more likely to be malignant
than oval nodes according to several studies [14]. Ill-
defined and irregular shaped nodes are features sugges-
tive of malignancy (Fig. 5).
Number of nodes
A cluster of normal nodes may suggest malignant
involvement but asymmetry in the pelvis is common,
making this sign less reliable [17].
Nodal characteristics
CT findings
Pelvic nodal metastases usually have a soft tissue-density,
but other features may be helpful in diagnosing metastatic
involvement.
Calcification is typically seen in rectal and ovarian
cancer.
A low-density central area of necrosis is seen in large
nodes greater than 2–3 cm.
Low-density ‘cystic’ nodes are seen typically in
testicular cancer.
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Figure 5 (a) and (b) Rectal cancer. Two patients with advanced disease showing enlarged ill-defined irregular
lymph nodes. Note: both nodes (arrows) have a heterogeneous signal intensity on these T2-weighted images.
Nodes frequently enhance with intravenous contrast
medium [18]. If inhomogeneous enhancement of a large
node is seen, this is more likely to be malignant, but
homogeneous enhancement may be due to benign or
malignant disease.
Avid enhancement suggests an aggressive tumour, a
similar pattern often being seen in the primary tumour
as well as in the lymph nodes.
Fatty infiltration indicates benign enlargement.
MR findings
T1-weighted images show nodes which have low signal
intensity but which are usually a little higher than normal
vessels.
T2-weighted images show intermediate signal inten-
sity. High signal intensity on fast spin-echo imaging may
obscure visualisation of nodes against pelvic fat.
Heterogeneous nodes of intermediate signal on T2-
weighted images are more likely to be malignant than
homogenous nodes (Fig. 5).
STIR sequence—high signal intensity is seen in
enlarged lymph nodes and metastases cannot be distin-
guished from benign enlargement.
Tumours may enhance in a similar manner to CT.
Signal intensity time curves may be helpful for
detecting nodal involvement in normal-sized nodes [19].
Pitfalls in diagnosis
Normal structures and pelvic pathology can be misinter-
preted as nodes. Common pitfalls include loops of bowel,
normal ovaries, vessels and aneurysms, lymphocoele,
haematoma or abscess and nerves, e.g. the hypogastric
plexus (Fig. 6).
These pitfalls are seen both with CT and MR. MR may
be helpful in elucidating problems on CT and vice versa.
Accuracy of imaging and impact of
positive and negative results on patient
management
The overall accuracy of CT and MR imaging in
detection of pelvic nodal disease is similar, with reported
accuracies of between 75–100%. Sensitivities range from
48–87% and specificities from 64–100% [20–24]. Low
sensitivities are the main problem with both techniques
due to the inability to identify nodal metastases in
normal or only minimally enlarged nodes. A recent study
comparing dynamic helical CT with dynamic MR in
patients with cervical cancer showed sensitivities of 64.7
and 70% respectively; specificities were 96.6 and 89.8%
respectively. Thus no significant difference in accuracies
with the techniques was observed using modern up-to-
date equipment [25].
Interpretation and appropriate weighting should be
given to the clinical importance of lymph node detection.
For example in patients with prostate cancer being
considered for pelvic lymphadenectomy, the diagnosis of
metastatic nodal involvement may preclude surgery and
thus the margin of error must be as small as possible.
However, in patients to be treated with radiotherapy, the
impact of a false-positive examination is less dramatic,
potentially allowing a larger margin of error in lymph
node detection.
As clinical practice develops, knowledge of nodal
status may be important, not so much for determining
whether or not to pursue a radical treatment approach,
but rather in selecting different radical options, for
example the type of surgery, the radiotherapy treatment
volume or the need for adjuvant therapy. This approach
is based on recent studies that have demonstrated that
selected patients with nodal disease are curable. For
example, the RTOG 75-06 study reported by Hanks et
al. [26] showed a 10-year cancer-free survival of 70%
in node-positive patients and in another recent study
of 790 patients with localised prostate cancer treated
128 J. E. Husband
(a) (b) (c)
Figure 6 (a) Diagram showing the hypogastric nerve plexus. (b) Coronal image demonstrating the
hypogastric plexus (arrow) on a T2-weighted MR sequence. (c) Axial image in the same patient demonstrating
branches of the plexus (arrow) adjacent to vessels.
with radical prostatectomy, lymph node dissection and
androgen deprivation, a 15-year disease specific survival
of 60% in node-positive patients was demonstrated.
New developments and approaches to
nodal staging
Reduction in size criteria
Oyen et al. [24] showed a sensitivity of 78% and
specificity of 97% in prostate cancer, using 6 mm as the
upper limit of normal on CT. Fukuda et al. [27] used 5 mm
as the upper threshold (thin 3 mm sections) and showed
accuracy, sensitivity, specificity and positive and negative
predictive values of 79.4, 85.7, 77.8, 50.0 and 95.5%
respectively on CT. Current evidence of normal-sized
nodes on CT and MR [14,16] suggests that reduction in
threshold to 6 mm MSAD as the upper limit of normal
might improve sensitivity. However the use of such
lower criteria also raises important practical issues related
to radiologists’ time and how best to deal with these
minimally enlarged nodes in a given clinical scenario.
Increased specificity
Oyen et al. [24] have shown improved specificity by
obtaining cytology from suspicious nodes greater than
6 mm in diameter. In their series, specificity was
improved from 96.6 to 100%.
Fast dynamic contrast-enhanced CT
Obtaining signal intensity semi-quantitative data of
contrast enhancement characteristics may be helpful for
distinguishing malignant from benign nodes [19]. Quanti-
tative measurements of capillary permeability of tumour
and nodes may provide more accurate assessment.
MR-guided biopsy of pelvic nodes
This also feasible but not yet generally performed in
routine clinical practice.
MR lymphography
MR lymphography using ultrasmall iron oxide par-
ticles (USIOP) already shows promise in identifying
metastases in normal-sized nodes and will shortly be
introduced into routine clinical practice [28].
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